HOUSE-WELLNESS-FOODS
3.5.2016 13:51:54 CEST | Business Wire | Press release
A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, reversing disease trends and increasing reproduction. The study, published in the International Journal of Scientific and Research Publications , Volume 6, Issue 3, March 2016, is welcome news for the East Asian fishing industry, which has been plagued by vibriosis, linked to the presence of Vibrio parahaemolyticus and other bacteria found in salt water. Feed LP20® is proven safe, and represents groundbreaking evidence of the effectiveness of heat-treated lactobacillus, as measured in conjunction with this crucial species.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160503005537/en/
Feed LP20® was developed for livestock and fisheries as an alternative to antibiotic regimens, and as a functional product for improving immune function and productivity. It contains 20% heat-killed Lactobacillus plantarum L-137 (HK L-137) . Heat treatment of HK L-137, the central ingredient of House Wellness Foods’ Feed LP20® and Immuno-LP20® , is key to those products’ effectiveness, making them stable long-term at varying temperatures, easily handled, even under pressure, and maintaining immunostimulant properties while resisting degradation by water and gastric acids.
HWF is regarded as a pioneer in the continuous study of HK L-137, and Immuno-LP20 has been hugely successful as an immunobiotic, enjoying prominence among health-conscious consumers in the U.S. and worldwide as a natural aid to the body’s innate ability to defend itself against seasonal illness and allergy.
A joint study conducted in cooperation with Vietnam’s Can Tho University proved conclusively that the addition of as little as 100 ppm of Feed LP20 boosts immune function in the shrimp population and improves survival and growth rates, which were significantly (P<0.05) higher compared to other feeds. Immune parameters consisted of total haemocyte count, differential haemocyte count, phenoloxidase activity, phagocytic activity and clearance efficiency. The study also showed a critical synergistic effect in conjunction with B-glucan, an activator of immune system functions in aquaculture.
House Wellness Foods is pursuing sales and promotion of Feed LP20 for livestock and aquaculture in support of these industries and in the hope of ameliorating the blight of worldwide hunger.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160503005537/en/
Contact:
House Wellness Foods
Onoda Satoru, +81-3-5211-7220
Onoda_Satoru@house-wf.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom